tiprankstipranks
Nolato AB Class B (GB:0OA9)
LSE:0OA9

Nolato AB (0OA9) Price & Analysis

0 Followers

0OA9 Stock Chart & Stats

kr52.00
kr0.45(0.94%)
At close: 4:00 PM EDT
kr52.00
kr0.45(0.94%)

Bulls Say, Bears Say

Bulls Say
Conservative Balance SheetMeaningful deleveraging and low net leverage give Nolato financial flexibility to absorb industry volatility, fund capacity expansion and pursue acquisitions without placing excessive pressure on future cash flows.
Strong Cash GenerationPositive operating and free cash flow supports self-funded investment, debt management and shareholder returns. Cash flow also exceeded reported earnings on a trailing basis, indicating useful cash conversion despite historical variability.
Medical Growth And Capacity ExpansionMedical contract manufacturing can deepen customer relationships and create durable program revenue. New capacity and the gradual GLP-1 volume ramp provide a multi-year avenue for growth as facilities move toward fuller utilization.
Bears Say
Sustained Margin PressureLower EBITA and margins indicate that recent growth is not yet translating fully into earnings. Persistent cost inflation, start-up expenses and elevated overhead could limit profitability until new programs scale and efficiencies improve.
Revenue And Free Cash Flow VariabilityThe uneven multi-year sales pattern and volatile cash generation reduce confidence in consistent compounding. This may reflect cyclical customer demand, program timing and working-capital movements that can complicate planning and investment.
End-market Weakness And Lower Capital EfficiencyWeakness in hygiene and automotive can restrain Engineered Solutions demand and dilute growth across the portfolio. At the same time, lower ROCE suggests ongoing investments have not yet produced their full economic return.

Nolato AB News

0OA9 FAQ

What was Nolato AB Class B’s price range in the past 12 months?
Nolato AB Class B lowest share price was kr45.82 and its highest was kr64.65 in the past 12 months.
    What is Nolato AB Class B’s market cap?
    Nolato AB Class B’s market cap is kr14.28B.
      When is Nolato AB Class B’s upcoming earnings report date?
      Nolato AB Class B’s upcoming earnings report date is Oct 29, 2026 which is in 60 days.
        How were Nolato AB Class B’s earnings last quarter?
        Nolato AB Class B released its earnings results on Jul 17, 2026. The company reported kr0.63 earnings per share for the quarter, missing the consensus estimate of kr0.698 by -kr0.068.
          Is Nolato AB Class B overvalued?
          According to Wall Street analysts Nolato AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Nolato AB Class B pay dividends?
            Nolato AB Class B does not currently pay dividends.
            What is Nolato AB Class B’s EPS estimate?
            Nolato AB Class B’s EPS estimate is 0.73.
              How many shares outstanding does Nolato AB Class B have?
              Nolato AB Class B has 241,786,940 shares outstanding.
                What happened to Nolato AB Class B’s price movement after its last earnings report?
                Nolato AB Class B reported an EPS of kr0.63 in its last earnings report, missing expectations of kr0.698. Following the earnings report the stock price went down -4.409%.
                  Which hedge fund is a major shareholder of Nolato AB Class B?
                  Currently, no hedge funds are holding shares in GB:0OA9
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Nolato AB Class B

                    Nolato AB (publ) is a Swedish enterprise that specializes in the creation, manufacturing, and commercialization of polymer-based products, utilizing plastics, silicones, and thermoplastic elastomers. Its extensive portfolio serves a diverse array of industries, including medical technology, pharmaceuticals, consumer electronics, telecommunications, automotive, and other industrial applications. The company maintains a global presence, operating in North America, various European countries (including Sweden), and Asia. Its offerings are wide-ranging: For clinical, chemical, forensic, research, and industrial testing laboratories, Nolato provides both disposable and reusable labware, encompassing products like pipette tips, deep-well plates, microtubes, and PCR items. It also supplies primary pharmaceutical packaging solutions designed for solids, creams, and ophthalmic preparations, along with customized production services. In the electronics sector, Nolato engineers, develops, and produces advanced components, subsystems, and complete packaged electronic devices. These include specialized items such as laser application parts and ceramics, consumer gadgets like fitness trackers, loudspeaker systems, thermostats, webcams, and heating elements for vaporizers. Furthermore, the company contributes to the automotive industry and delivers specialized solutions for electromagnetic interference (EMI) shielding, thermal management, and silicone-based sealing and damping. It also furnishes plastic components and assemblies for food processing equipment, such as coffee machines and blenders. Established in 1938, the company was originally known as Nordiska Latexfabriken i Torekov AB before officially changing its name to Nolato AB (publ) in 1982. Its corporate headquarters are located in Torekov, Sweden.

                    Nolato AB (0OA9) Earnings & Revenues

                    0OA9 Company Deck

                    0OA9 Earnings Call

                    Q2 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call presents a generally positive operational picture with continued top-line growth (currency-adjusted), strong cash generation, a notable 19% materials surge, and progress on strategic capacity expansions (Hungary, Malaysia, Poland). These positives are tempered by margin pressure from higher raw material costs (~SEK 20m), start-up costs in Medical (~SEK 10m), a SEK 6m severance item and somewhat elevated group costs related to M&A activity. Segment-specific soft patches (hygiene and automotive) and a modest dip in ROCE were noted but appear manageable given the strong balance sheet and stated ability to pass on costs and ramp volumes. Overall, the highlights outweigh the lowlights, driven by growth, cash flow and a strong balance sheet enabling future M&A and capacity build-out.View all GB:0OA9 earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Lifco Ab
                    AddLife AB
                    Arjo AB
                    Xvivo Perfusion AB
                    Bergman & Beving AB Class B
                    Popular Stocks